Dr. Conaghan has received honoraria (less than $10,000) from Merck Sharp & Dohme and Novartis. Dr. Emery has received consulting fees and/or honoraria (less than $10,000) from Merck Sharp & Dohme, Novartis, Roche, and Aventis.
Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis
Version of Record online: 27 APR 2006
Copyright © 2006 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 54, Issue 5, pages 1410–1414, May 2006
How to Cite
Jarrett, S. J., Conaghan, P. G., Sloan, V. S., Papanastasiou, P., Ortmann, C.-E., O'Connor, P. J., Grainger, A. J. and Emery, P. (2006), Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis & Rheumatism, 54: 1410–1414. doi: 10.1002/art.21824
- Issue online: 27 APR 2006
- Version of Record online: 27 APR 2006
- Manuscript Accepted: 13 FEB 2006
- Manuscript Received: 29 JUN 2005
- Novartis Pharma AG
- 10World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48: 206–8.
- 13Bone edema scored on magnetic resonance imaging scans of the dominant carpus at presentation predicts radiographic joint damage of the hands and feet six years later in patients with rheumatoid arthritis. Arthritis Rheum 2003; 48: 1814–27., , , , , , et al.